BI 655064

Drug Profile

BI 655064

Alternative Names: BI-655064

Latest Information Update: 13 Oct 2016

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CD40 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lupus nephritis
  • Phase I Immune thrombocytopenic purpura; Rheumatoid arthritis

Most Recent Events

  • 28 Sep 2016 Boehringer Ingelheim terminates a phase I trial for Immune thrombocytopenic purpura in the US (NCT02009761)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in Germany (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(Treatment-experienced) in Czech Republic (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top